Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

Objective: To characterize its dose-response relationship, BI 655064 (an anti-CD40 monoclonal antibody) was tested as an add-on to mycophenolate and glucocorticoids in patients with active lupus nephritis (LN). Methods: A total of 121 patients were randomized (2:1:1:2) to receive placebo or BI 65506...

Full description

Saved in:
Bibliographic Details
Main Author: Jayne D.R.
Other Authors: Mahidol University
Format: Article
Published: 2023
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/88853
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University